Moses A M, Notman D D
Arch Intern Med. 1982 Jan;142(1):128-9.
Secondary hyperparathyroidism developed on two separate occasions in a patient taking an oral contraceptive (OC) in a mixture of norethindrone and mestranol (Ortho-Novum 1/80). The probable cause of this condition is an estrogenic inhibition of the calcium mobilizing effect of parathyroid hormone (PTH) or vitamin D. The possible consequences of OC therapy in this patient and patients like her include those of milk hypocalcemia, moderate hypophosphatemia, or the neurotoxic actions of excessive levels of circulating PTH. One should also consider the possible role of OC therapy in patients with unexplained parathyroid hyperplasia and with tertiary hyperparathyroidism.
一名服用炔诺酮和炔雌醇混合物（炔诺酮炔雌醇片1/80）口服避孕药（OC）的患者曾两次出现继发性甲状旁腺功能亢进。这种情况的可能原因是雌激素对甲状旁腺激素（PTH）或维生素D的钙动员作用的抑制。该患者及类似患者接受OC治疗的可能后果包括乳钙血症、中度低磷血症或循环中PTH水平过高的神经毒性作用。对于原因不明的甲状旁腺增生和三发性甲状旁腺功能亢进患者，也应考虑OC治疗的可能作用。
